[Diflunisal, a new analgesic, and oxyphenbutazone in the treatment of sprains and dislocations (author's transl)].
In a randomized double-blind study efficacy and tolerance of diflunisal, 375 mg twice daily, and oxyphenbutazone, 200 mg twice daily, were compared in 40 patients (aged 21 to 70 years, average 38 years), with moderate or severe complaints after spraining or dislocating ankle or wrist. The drugs were given for five days. Both proved to be highly efficacious, diflunisal slightly more so. Among the 20 patients in the diflunisal group one developed diarrhoea, another gastritis; in the oxyphenbutazone group one developed gastritis, another herpetiform pustules. There were no clinically significant abnormalities in routine biochemical tests.
D000328:Adult; D000368:Aged; D000843:Ankle Joint; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D005756:Gastritis / Q000139:chemically induced; D006801:Humans; D004204:Joint Dislocations / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010113:Oxyphenbutazone / Q000627:therapeutic use*; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced; D013180:Sprains and Strains / Q000188:drug therapy*; D014954:Wrist Injuries / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012459:Salicylates; D010113:Oxyphenbutazone
Diflunisal, ein neues Analgetikum, und Oxyphenbutazon bei der Behandlung von Zerrungen und Verrenkungen.